Paediatric Patients with Hypophosphatasia Receiving Investigational Asfotase Alfa Had Sustained Improvements in Growth and Physical Function
3 minutes ago - BusinessWire via Dow Jones News
--Data from Phase 2 Extension Studies Presented at ESPE Meeting-- DUBLIN, Ireland--(BUSINESS WIRE)--September 19, 2014-- Alexion Pharmaceuticals today announced that researchers presented data from the open-label extension phases of two Phase 2 studies of asfotase alfa, an investigational enzyme replacement therapy, in paediatric patients with hypophosphatasia (HPP).(1,2) In the ongoing studies, researchers observed sustained improvements in growth, strength, physical function, and ot...